Streetbeat News

Equity Actions

SE

Sea's (NYSE:SE) short interest has increased by 3.13%, with 23.22 million shares sold short, representing 7.57% of available shares. It would take 3.79 days to cover these short positions. While high short interest can indicate bearish sentiment, it doesn't necessarily predict a price drop. Sea has a higher short interest than its peer group average of 3.41%.

Portfolio Pulse from Benzinga Insights

January 29, 2024 | 8:15 pm

HTGC

Hercules Capital (NYSE:HTGC) has been the subject of diverse analyst opinions over the past three months, with 5 analysts offering ratings ranging from neutral to overweight. The average 12-month price target is $17.8, slightly down from the previous $17.83. Analysts from Wells Fargo and Piper Sandler have raised their price targets, while Piper Sandler also lowered one target. The company faces challenges with a -29.4% revenue decline as of September 30, 2023, but maintains a high net margin of 54.32%. Its ROE and ROA are below industry averages, and it has a high debt-to-equity ratio of 0.99.

Portfolio Pulse from Benzinga Insights

January 29, 2024 | 8:00 pm

REGN

Regeneron Pharmaceuticals (NASDAQ:REGN) has been evaluated by 14 analysts over the last three months, with diverse opinions ranging from bullish to bearish. The average 12-month price target for REGN is $963.57, with a high of $1076.00 and a low of $800.00, marking a 6.73% increase from the previous target of $902.83. Analysts have made various rating actions, including maintaining, raising, and lowering their stances and price targets. Regeneron is involved in developing treatments for diseases and has several marketed products. The company's financial performance shows a revenue growth of 14.53%, a high net margin of 29.97%, an ROE of 4.12%, an ROA of 3.21%, and a low debt-to-equity ratio of 0.11.

Portfolio Pulse from Benzinga Insights

January 29, 2024 | 8:00 pm

ZM

Zoom Video Comms Inc. (NASDAQ:ZM) has seen a slight drop in its stock price in the current session and has experienced declines over the past month and year. Investors are examining the company's P/E ratio, which is lower than the Software industry average, suggesting that the stock might be undervalued or that shareholders have low growth expectations.

Portfolio Pulse from Benzinga Insights

January 29, 2024 | 7:30 pm

TSLA

Tesla Inc's Chair, Robyn Denholm, is set to sell up to $50 million worth of her Tesla stock, as per a new SEC filing. The planned sale of up to 281,116 shares is part of a trading arrangement set to expire on August 16, 2024, and follows her substantial compensation in 2022, including over 600,000 shares. This news comes amid discussions of CEO Elon Musk's next compensation plan, which may involve 25% control over Tesla's shares. Tesla previously faced a lawsuit over excessive board compensation, resulting in a $735 million settlement.

Portfolio Pulse from Benzinga EV Insights

January 29, 2024 | 7:29 pm

BE

BFRG

CDLX

PBLA

SNCE

SOFI

U.S. stocks saw a slight increase, with the Nasdaq Composite up by 75 points. The Dow and S&P 500 also experienced modest gains. Consumer discretionary shares led the gains, while energy shares declined following a 1.3% drop in crude oil prices. Science 37 Holdings (SNCE) surged 16% after agreeing to be acquired by eMed. SoFi Technologies (SOFI) jumped 16% on strong quarterly revenue, and Cardlytics (CDLX) rose 28% after a settlement agreement and updated Q4 results. Conversely, Panbela Therapeutics (PBLA) plummeted 67% due to a public offering, Bullfrog AI Holdings (BFRG) fell 24% after a shelf offering, and Bloom Energy (BE) dropped 7% after a downgrade by B of A Securities. The Federal Reserve Bank of Dallas reported a decline in Texas manufacturing activity.

Portfolio Pulse from Avi Kapoor

January 29, 2024 | 7:24 pm

PBLA

Panbela Therapeutics, Inc. (NASDAQ:PBLA) shares plummeted by 65.5% to $1.47 after announcing a public offering priced at approximately $9 million. Other stocks experienced significant movements in Monday's mid-day session, with various companies showing notable gains and losses. Gainers included Palisade Bio, Inc. (NASDAQ:PALI), OneMedNet Corporation (NASDAQ:ONMD), and Revelation Biosciences, Inc. (NASDAQ:REVB), among others. Losers featured SMX (Security Matters) Public Limited Company (NYSE:SMX), Inspire Veterinary Partners, Inc. (NASDAQ:IVP), and Bullfrog AI Holdings, Inc. (NASDAQ:BFRG), among others.

Portfolio Pulse from Avi Kapoor

January 29, 2024 | 7:09 pm

RXST

Over the past three months, 8 analysts have provided ratings for RxSight (NASDAQ:RXST), with sentiments ranging from bullish to bearish. The average 12-month price target for RXST is $42.38, with a high of $54.00 and a low of $30.00, marking a 3.37% increase from the previous target of $41.00. Analysts from firms like Oppenheimer, Needham, Wells Fargo, Stifel, and Morgan Stanley have updated their ratings and price targets, reflecting their views on the company's market performance. RxSight, a medical technology company, has shown a revenue growth of 75.97% as of September 30, 2023, but struggles with profitability and efficiency, as indicated by its net margin of -55.93%, ROE of -7.79%, and ROA of -6.58%. The company has a low debt-to-equity ratio of 0.02.

Portfolio Pulse from Benzinga Insights

January 29, 2024 | 7:00 pm

COIN

Coinbase Global, Inc. (NASDAQ:COIN) stock is trading higher, influenced by the recent increase in Bitcoin's price and a positive analyst upgrade. Bitcoin's price has risen over 8% in the past five days, positively impacting crypto-related stocks like Coinbase. Oppenheimer analyst Owen Lau upgraded Coinbase from Perform to Outperform with a price target of $160, citing potential favorable outcomes in ongoing litigation with the SEC and benefits from the approval of spot Bitcoin ETFs.

Portfolio Pulse from Erica Kollmann

January 29, 2024 | 6:07 pm

MUR

Analysts have mixed views on Murphy Oil (NYSE:MUR), with recent ratings ranging from bullish to bearish. The average 12-month price target is $50.17, a slight decrease from the previous $51.20. Analysts from UBS, Piper Sandler, Keybanc, and Truist Securities have adjusted their ratings and price targets, reflecting changes in market dynamics and company performance. Murphy Oil, an independent oil and gas company, reported a revenue decline of -11.69% as of December 31, 2023, and faces challenges in profitability and asset utilization, with a net margin of 13.81%, ROE of 2.17%, and ROA of 1.18%. The company's debt-to-equity ratio is below the industry average at 0.39.

Portfolio Pulse from Benzinga Insights

January 29, 2024 | 6:00 pm